This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): GA201, RO5083945, RG7160
Description: The anti-EGFR MAb GA201 is a recombinant, humanized, and glycoengineered MAb ofthe immunoglobulin G1 (IgG1) subclass directed against EGFR/HER1. GA201 hasdemonstrated high-affinity binding to EGFR with inhibition of EGF ligand binding, EGFR/HER2heterodimerization, EGFR downstream signaling and cell proliferation, and induction of celldeath. In addition, GA201 was engineered for high ADCC potency. In preclinical models,GA201 has demonstrated greater activity than other anti-EGFR antibodies.
Deal Structure: GA201 was originally developed by GlycArt.
In July 2005, Roche announced that it signed an agreement to acquire 100% of GlycArt.
Additional information available to subscribers only: